FINWIRES · TerminalLIVE
FINWIRES

$HIMS

39 stories mentioning HIMSUpdated 12d ago

Every FINWIRES story that references HIMS, newest first.

What are analysts saying about HIMS?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on HIMS?

Wire

Hims & Hers Health Expands in Australia With Pilot Rebrand

Hims & Hers Health (HIMS) is launching the Hims brand in Australia, rebranding Pilot, the men's health platform it acquired through its takeover of Eucalyptus earlier this year.Pilot becomes Hims effective immediately, and existing patients retain their treatment plans and provider relationships, the company said Monday in a statement.The company said the rebrand expands access to 24/7 care, up from Pilot's previous 12-hour availability.Price: $29.67, Change: $+0.82, Percent Change: +2.86%

$HIMS
Insider Trading

Hims & Hers Health Insider Sold Shares Worth $2,205,192, According to a Recent SEC Filing

Oluyemi Okupe, Chief Financial Officer, on June 18, 2026, sold 64,771 shares in Hims & Hers Health (HIMS) for $2,205,192. Following the Form 4 filing with the SEC, Okupe has control over a total of 264,117 Class A common shares of the company, with 264,117 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1773751/000177375126000210/xslF345X05/wk-form4_1787087043.xml

$HIMS
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) decreased less than 0.1%.In corporate news, Tactile Systems Technology (TCMD) shares fell past 17% after it reported late Monday its Q2 results and lowered its revenue guidance for the full year.Alamar Biosciences (ALMR) reported a narrower Q2 net loss and sales above consensus late Monday. Its shares surged past 32%.Hims & Hers Health (HIMS) shares fell 2.5%. Q2 results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said.Eli Lilly (LLY) committed to use Veeva Systems' (VEEV) Veeva Vault CRM globally. Lilly shares were down 1.3%, and Veeva added 1%.

$ALMR$HIMS$LLY$TCMD$VEEV
Sectors

Sector Update: Healthcare Stocks Softer Tuesday Afternoon

Healthcare stocks declined Tuesday afternoon with the NYSE Healthcare Index shedding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.3%.The iShares Biotechnology ETF (IBB) rose 0.3%.In corporate news, Hims & Hers Health (HIMS) shares fell 1.9%. Q2 results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said.Eli Lilly (LLY) committed to use Veeva Systems' (VEEV) Veeva Vault CRM globally. Lilly shares fell 0.9%, and Veeva added 1%.AC Immune's (ACIU) ACI-7104, for the potential treatment of early-stage Parkinson's disease, received US Food and Drug Administration fast-track designation and investigational new drug clearance. The shares jumped 14%.

$ACIU$HIMS$LLY$VEEV
Sectors

Sector Update: Healthcare

Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) rose 0.3%In corporate news, Hims & Hers Health (HIMS) shares were down 3.8% following its Q2 results. The results were mixed, with upside in its US business from branded GLP-1 strength and a ramp in testosterone offset by disappointing gross margin and weak free cash flow, Morgan Stanley said in a note.

$HIMS
Wire

Hims & Hers Health Sees Mixed Q2 as Gross Margin, FCF Weigh, Morgan Stanley Says

Hims & Hers Health (HIMS) reported a mixed Q2, with upside in its US business from branded GLP-1 strength and a ramp in testosterone, offset by disappointing gross margin and weak free cash flow, Morgan Stanley said Tuesday in a note.Management expects Q3 revenue of $880 million to $900 million and EBITDA of $75 million to $95 million, compared with Street estimates of $777 million and $93 million, respectively. For 2026, the midpoint of sales and EBITDA guidance is now $3.2 billion and $300 million, 10% above and 4% below Street estimates, respectively, according to the note.Morgan Stanley raised its revenue estimates, driven by Eucalyptus and slightly better domestic trends. It lowered its 2026 and 2027 gross margin estimates to 64.2% and 64% from 70% and 69% previously, partly offset by reduced operating expenses, led by marketing, the note added.This reflects a changing mix and Hims' prioritization of growth over gross margins. The brokerage also lowered its 2026 EBITDA estimate to $300 million from $312 million, while leaving its 2027 estimate unchanged at $371 million.Morgan Stanley raised its price target on Hims & Hers Health to $28 from $21, with an equal weight rating.Shares of Hims & Hers Health were down 2.4% in Tuesday trading.Price: $31.00, Change: $-0.77, Percent Change: -2.44%

$HIMS
Asia Markets

Update: US Equity Futures Mostly Flat Pre-Bell as US-Iran Stalemate Persists

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were mostly flat pre-bell Tuesday as the US and Iran remained at a stalemate regarding negotiations to reopen the Strait of Hormuz.Dow Jones Industrial Average futures were 0.1% higher, S&P 500 futures were up 0.2%, and Nasdaq futures were 0.3% higher.In response to Iran's conditions for reopening the waterway, US President Donald Trump said Monday that the Middle Eastern nation should pay reparations of its own for damage done over the past 50 years. "If there's damages to be paid, I think Iran should pay those damages," multiple reports quoted Trump as saying.Iranian Foreign Minister Abbas Araghchi had earlier said that reopening the strait would be partly conditional on the US paying for damage caused during the conflict between the two countries.Traders took note of the latest round of earnings, with Sea (SE) posting higher Q2 earnings and revenue.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 0.2% at $87.93 per barrel and US West Texas Intermediate crude 0.4% higher at $82.48 per barrel.The existing home sales report, scheduled for release at 10 am ET, is expected to show a decrease of 1% for July after a 2.4% fall in the prior month.In other world markets, Hong Kong's Hang Seng ended 1.1% lower and China's Shanghai Composite finished 0.8% lower, while Japan's Nikkei was closed for a public holiday. Meanwhile, the UK's FTSE 100 was 0.1% higher, and Germany's DAX index was 0.2% higher in Europe's early afternoon session.In equities, Sea stock was up more than 10% after the company reported its Q2 financial results. Nvidia (NVDA) shares rose 1.6% after the chipmaker said it partnered with six major financial institutions to raise more than $500 billion in third-party capital for the development of artificial intelligence infrastructure. SK Hynix (SKHY) stock was 2.1% higher after a Seoul Economic Daily report that the company plans to resume construction at its second NAND flash facility in Dalian, China, to boost local output by about 50%.On the losing side, Rocket Lab's (RKLB) shares fell 3.7% after the company's Q2 loss narrowed less than analysts' consensus. Hims & Hers Health (HIMS) was down 6.9% after the company reported late Monday it swung to a Q2 loss.

Dow JonesNasdaq CompositeS&P 500$HIMS$NVDA$RKLB$SE$SKHY
Stocks Mostly Up Pre-Bell as Investors Assess Uncertainty Over US-Iran Deal
US Markets

Stocks Mostly Up Pre-Bell as Investors Assess Uncertainty Over US-Iran Deal

US equity markets were mostly trending higher before the open Tuesday as investors weigh fading optimism that the US and Iran would reach a quick resolution to their conflict and reopen the Strait of Hormuz.The S&P 500 edged up 0.1% and the Nasdaq added 0.3% in premarket activity, while the Dow Jones Industrial Average was slightly in the red. The indexes closed Monday's trading session lower.In a social media post Monday, President Donald Trump demanded compensation from Iran for casualties caused by its conflicts, attacks and suppression of protests."I see that representatives of the Islamic Republic of Iran are asking for compensation for the damage done to them during the last five month military conflict," according to Trump. "I am likewise demanding compensation from Iran, for all of the people that they have killed and gravely wounded with their roadside bombs and many conflicts, for which they are famous, as led initially by General Soleimani."Iranian Foreign Minister Abbas Araghchi recently said there was no possibility of restarting negotiations with the US over a peace deal until it stops violating the memorandum of understanding signed between the two countries in June and compensates Tehran for those breaches, according to Iran-based Tasnim News Agency.Trump recently indicated to the media that he's prepared to exert greater economic pressure on Iran instead of launching another military attack.West Texas Intermediate crude oil increased 2% to $83.77 a barrel before the opening bell, while Brent advanced 1.8% to $89.30."Oil prices remain supported by uncertainty surrounding the Strait of Hormuz," ING Bank said in a report Monday. "Significant hurdles remain before any broader agreement is reached."US Treasury yields were moving higher in premarket action, with the two-year rate rising 1.4 basis points to 4.25% and the 10-year rate gaining 2.7 basis points to 4.73%.Shares of Nvidia (NVDA) inclined 1% pre-bell after the tech bellwether said it has partnered with six of Wall Street's largest financial institutions to raise more than $500 billion in third-party capital for the development of artificial intelligence infrastructure across its ecosystem.Hims & Hers Health (HIMS) dropped 6.2% after the company reported a wider-than-expected second-quarter loss. Trump Media & Technology (DJT) decreased 0.9% following an 8% decline at the close of Monday as it announced its latest quarterly earnings.Sea (SE), Cardinal Health (CAH), Elbit Systems (ESLT), On Holding (ONON), Tencent Music Entertainment (TME), and Smithfield Foods (SFD) are scheduled to release their latest financial results before the bell, among others. Lumentum (LITE), CoreWeave (CRWV) and Super Micro Computer (SMCI) report their earnings after the markets close.Tuesday's economic calendar has the existing home sales report for July at 10 am ET. The National Federation of Independent Business small business optimism index posted a 2.4-point increase for July to 99.8.Gold rose 0.4% to $4,438 per troy ounce, while bitcoin traded up 0.4% at $64,180.

Dow JonesNasdaq CompositeS&P 500$ARMK$CAH$CRWV$DJT$ESLT$HIMS$LITE$NVDA$ONON$SE$SFD$SMCI$TME
Stocks Mostly Up Pre-Bell as Traders Assess Middle East Developments, Await Key Inflation Data
US Markets

Stocks Mostly Up Pre-Bell as Traders Assess Middle East Developments, Await Key Inflation Data

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as traders monitor the latest developments in the Middle East and await key inflation data later in the week.The S&P 500 edged up 0.1% and the Nasdaq increased 0.4% in premarket activity, while the Dow Jones Industrial Average slipped 0.2%. The indexes finished Friday trading in the green, with the S&P 500 notching a new closing high.Iranian Foreign Minister Abbas Araghchi said Sunday that Tehran isn't in direct talks with Washington to end their war and reopen the Strait of Hormuz, CNBC reported, citing state media. Araghchi noted that the US will still have to meet Iran's conditions to open the strait, even if a deal is finalized with Oman on the crucial waterway.West Texas Intermediate crude oil inclined 0.9% to $78.85 a barrel before the open, while Brent gained nearly 1% to $84.38.President Donald Trump has signaled that he's prepared to let economic pressure take its toll on Iran instead of mounting another military attack, Axios reported Sunday."We are low-keying it," Trump reportedly said in a phone call, according to Axios. "We are only semi-negotiating with them. We are just watching Iran with its huge inflation and the fact they have no money."With no major economic data scheduled for Monday, traders await the consumer price index for July on Wednesday, followed by wholesale prices and retail sales for the same month on Thursday and Friday, respectively.US Treasury yields were mixed in premarket action, with the two-year rate nudging 0.6 basis points higher to 4.21% while the 10-year rate retreated 0.4 basis points to 4.66%.Last week, official data showed that nonfarm payrolls unexpectedly fell in July, marking the first decline since February. The unemployment rate decreased to 4.1%, the lowest since June 2025 when it stood at the same level.Ferguson Enterprises (FERG), Axsome Therapeutics (AXSM) and monday.com (MNDY) report their latest financial results before the bell, among others. Rocket Lab (RKLB) and Hims & Hers Health (HIMS) post their earnings after the markets close.Shares of Plug Power (PLUG) advanced 5% pre-bell while Palantir Technologies (PLTR) was off 1.4% following a 10% jump at the close of Friday. Super Micro Computer (SMCI) climbed 3.2%.Gold inched up 0.1% to $4,402 per troy ounce, while bitcoin slipped 0.3% to $64,972.

Dow JonesNasdaq CompositeS&P 500$AXSM$FERG$HIMS$MNDY$PLTR$PLUG$RKLB$SMCI
Wire

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.8%.The iShares Biotechnology ETF (IBB) shed 0.9%.In corporate news, Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission, the State of California, and the Utah Division of Consumer Protection, for allegedly sharing users' data with Meta (META), Snap (SNAP) and other online advertising companies, court documents show. Hims & Hers Health shares fell past 14%.UnitedHealth (UNH) may lose significant funding as the Trump administration plans to terminate a Medicare prescription drug subsidy program, The Wall Street Journal reported. The government will end the $3.6 billion subsidy after 2026, which would have directed more than half of its funds to UnitedHealth next year, the report quoted the administration officials as saying. UnitedHealth shares were down 1.8%.Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. Its shares were down 1.5%.NeoGenomics (NEO) shares jumped past 15% after it reported better-than-expected Q2 results.

$BSX$HIMS$NEO$UNH
Wire

Update: FTC Suing Hims & Hers for Allegedly Sharing User Data With Meta, Snap

(Updates with Hims' official statement in the third paragraph.)Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission, the State of California, and the Utah Division of Consumer Protection, for allegedly sharing users' data with Meta Platforms (META), Snap (SNAP) and other online advertising companies, court documents show.The suit, filed in the US District Court for the Northern District of California, also alleges Hims charged consumers unwanted prescription medication subscriptions without their consent, and enrolls consumers in subscription plans "almost immediately after receiving consumers' medical intake forms.""This lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims," Hims said on X. "This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense. We are confident in our position and will vigorously defend ourselves against these baseless claims."Hims & Hers shares were down over 11% in Wednesday trading.Price: $25.68, Change: $-3.65, Percent Change: -12.43%

$HIMS$META$SNAP
Wire

Update: FTC Suing Hims & Hers for Allegedly Sharing User Data With Meta, Snap

(Updated with information from court documents in the first two paragraphs.)Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission, the State of California, and the Utah Division of Consumer Protection, for allegedly sharing users' data with Meta Platforms (META), Snap (SNAP) and other online advertising companies, court documents show.The suit, filed in the US District Court for the Northern District of California, also alleges Hims charged consumers unwanted prescription medication subscriptions without their consent, and enrolls consumers in subscription plans "almost immediately after receiving consumers' medical intake forms."Hims & Hers Health didn't immediately reply to a request for comment from.Hims & Hers shares were down over 11% in Wednesday trading.Price: $25.85, Change: $-3.47, Percent Change: -11.83%

$HIMS$META$SNAP
Sectors

Sector Update: Healthcare Stocks Edge Lower in Afternoon Trading

Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) fell 0.7%.In corporate news, Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission for allegedly sharing users' data with Meta (META), Snap (SNAP) and other companies, Reuters reported. Hims & Hers Health shares dropped 11%.UnitedHealth (UNH) may lose significant funding as the Trump administration plans to terminate a Medicare prescription drug subsidy program, The Wall Street Journal reported. The government will end the $3.6 billion subsidy after 2026, which would have directed more than half of its funds to UnitedHealth next year, the report quoted the administration officials as saying. UnitedHealth shares were down 1.4%.Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. Its shares were up 0.8%.

$BSX$HIMS$UNH
Wire

Market Chatter: FTC Suing Hims & Hers Health for Allegedly Sharing User Data With Meta, Snap

Hims & Hers Health (HIMS) is being sued by the US Federal Trade Commission for allegedly sharing users' data with Meta Platforms (META), Snap (SNAP) and other online advertising companies, Reuters reported Wednesday, citing an FTC spokesperson.Hims & Hers Health didn't immediately reply to a request for comment from.Hims & Hers Health shares were down by more than 12% in Wednesday trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $25.09, Change: $-4.23, Percent Change: -14.43%

$HIMS$META$SNAP
Wire

FTC Suing Hims & Hers Health for Allegedly Sending User Info to Meta and Snap, Reuters Reports

FTC Suing Hims & Hers Health for Allegedly Sending User Info to Meta and Snap, Reuters Reports

$HIMS$META$SNAP
Wire

Street Color: Hims & Hers Health Facing US FTC's Lawsuit Over Alleged Data Sharing, Reuters Says

Street Color: Hims & Hers Health Facing US FTC's Lawsuit Over Alleged Data Sharing, Reuters Says

$HIMS
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) eased 0.2%.In corporate news, short seller Culper Research said Wednesday it has taken a short position in Tarsus Pharmaceuticals (TARS), alleging the commercialization of Xdemvy relies on a Medicare copay assistance structure that "raises serious Anti-Kickback Statute concerns." Tarsus shares were down 3.6%.Can-Fite BioPharma (CANF) shares surged 56% after it said its phase 2a trial of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.Hims & Hers Health (HIMS) shares jumped past 8% after BofA Securities raised its price target to $36 from $25, while keeping its neutral rating.BridgeBio Pharma (BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street, with participation from HealthCare Royalty, a KKR (KKR) business, to fund upcoming product launches and pipeline development. BridgeBio shares were up 0.3%.

$BBIO$CANF$HIMS$TARS
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) was 0.1% lower.In corporate news, Hims & Hers Health (HIMS) shares jumped nearly 9% after BofA Securities lifted the company's price target to $36 from $25, while keeping its neutral rating.Can-Fite BioPharma (CANF) shares surged 44% after it said its phase 2a trial of Namodenoson in advanced pancreatic cancer met its primary safety endpoint and showed durable survival in a subset of heavily pretreated patients.BridgeBio Pharma (BBIO) has raised up to $1 billion in convertible preferred equity led by Sixth Street, with participation from HealthCare Royalty a KKR (KKR) business, to fund upcoming product launches and pipeline development. BridgeBio shares were down 0.6%.

$BBIO$CANF$HIMS
Sectors

Sector Update: Healthcare

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, Hims & Hers Health (HIMS) shares jumped past 8% after BofA Securities lifted the company's price target to $36 from $25, while keeping its neutral rating.

$HIMS
Wire

BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating

Hims & Hers Health (HIMS) has an average rating of Hold and mean price target of $29.27, according to analysts polled by FactSet.Price: $37.35, Change: $+2.68, Percent Change: +7.73%

$HIMS

Showing 1-20 of 39

Track with the FINWIRES app suite

FolioX
FolioX
Track HIMS in your portfolio
WheelAI
WheelAI
Analyze HIMS options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HIMS